MARKSANS PHARMA. share price has zoomed 6% and is presently trading at Rs 298.5.
Meanwhile, the BSE HEALTHCARE index is at 44,566.1 (up 1.4%).
Among the top gainers in the BSE HEALTHCARE index today are Divis Laboratories (up 5.5%) and ERIS LIFESCIENCES (up 3.7%).
SUVEN PHARMACEUTICALS (down 1.8%) and HIKAL CHEMIC (down 0.7%) are among the top losers today.
Over the last one year, MARKSANS PHARMA. has moved up from Rs 105.8 to Rs 298.5, registering a gain of Rs 192.7 (up 182.1%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,979.6 to 44,566.1, registering a gain of 59.3% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 174.8%), Glenmark Pharma (up 122.3%) and SUVEN PHARMACEUTICALS (up 106.9%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 81,965.2 (up 0.4%).
The top gainers among the BSE Sensex today are Bajaj Finance (up 2.6%) and Axis Bank (up 2.2%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 25,117.6 (up 0.4%). Shriram Transport and Trent are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,512.4 to 81,965.2, registering a gain of 16,452.8 points (up 25.1%).
MARKSANS PHARMA. net profit grew 26.4% YoY to Rs 891 million for the quarter ended June 2024, compared to a profit of Rs 704 million a year ago. Net sales rose 18.1% to Rs 5,906 million during the period as against Rs 5,000 million in April-June 2023.
For the year ended March 2024, MARKSANS PHARMA. reported 18.7% increase in net profit to Rs 3,149 million compared to net profit of Rs 2,653 million during FY23. Revenue of the company grew 17.6% to Rs 21,774 million during FY24.
The current Price to earnings ratio of MARKSANS PHARMA., based on rolling 12 month earnings, stands at 40.6.
Equitymaster requests your view! Post a comment on "MARKSANS PHARMA. Gains 6%; BSE HEALTHCARE Index Up 1.4%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!